Introduction
liver cancer is one of the most common cancers worldwide and the third most common cause of cancer-related mortality [1] [2] [3] . Both the incidence and mortality of liver cancer are rising. Over 80 % of liver cancer cases are classified as hepatocellular carcinoma (HCC), characterized by late-stage diagnosis and a poor prognosis. For most patients with advanced stages of the disease, therapeutic options are still inadequate. Currently, sorafenib, a multikinase inhibitor is the only targeted therapeutic drug approved for treatment of advanced HCC [4] . However, too often patients either fail initial sorafenib therapy or develop resistance 1 3 after initial response. Identification of new drugs targeting different cellular pathways is clearly needed.
transport between the nucleus and the cytoplasm is a fundamental process of eukaryotic cells. exportin-1 (XPO1, CrM1) is one of several nuclear export receptors, which is essential for nuclear export of numerous proteins as well as rna molecules [5, 6] . Interestingly, XPO1 is the sole nuclear exporter responsible for the transport of the majority of major tumor suppressors and growth regulatory proteins, such as p53, p27, FOXO1, IκB, cyclin B1, cyclin D1 and survivin [7, 8] . XPO1 expression levels are up-regulated in a number of solid tumors (glioblastoma, ovarian, pancreatic and cervical cancers) [9] [10] [11] [12] and hematological malignancies [acute myeloid leukemia (aMl), chronic lymphocytic leukemia (Cll), non-Hodgkin's lymphomas (nHl), multiple myeloma (MM), chronic myelogenous leukemia (CMl) and B cell acute lymphoblastic leukemia (B-all)] [13] [14] [15] [16] [17] [18] . the increase in XPO1 levels leads to miss-localization of tumor suppressors and cell cycle regulators which in turn results in their inactivation or aberrant activation. Indeed, overexpression of XPO1 is associated with poor prognosis and resistance to chemotherapy. Inhibition of XPO1 was, therefore, proposed as an attractive antineoplastic therapeutic strategy. However, initial XPO1 inhibitors, of which leptomycin B (lMB) is the most well known, showed limited clinical applicability due to severe toxicity and minimal efficacy potentially due to off target activity [7, 8, 19, 20] .
XPO1 binds to its cargo proteins by recognizing a hydrophobic, leucine-rich nuclear export signal (neS) [21, 22] . recently, a new class of potent and slowly reversible smallmolecule covalent inhibitors of XPO1, known as selective inhibitors of nuclear export (SIne), were developed (Karyopharm therapeutics Inc.). SIne selectively bind to Cys528 located in the neS-binding groove of XPO1, thereby inhibiting XPO1 binding to its target proteins [17, 23, 24] . these compounds exert anti-tumor activity in several malignances in vitro as well as in animal models [13, 18] . Importantly, SIne showed minimal toxicities in normal cells. Based on these promising results, phase one clinical trials of the SIne compound, KPt-330, are ongoing in patients with either relapsed or refractory hematologic malignancies (nCt01607892) and solid tumors (nCt01607905, nCt01896505). In the current study, we investigated the anti-cancer potential of SIne against HCC cell lines and in a HCC xenograft in vivo model.
Martials and methods

Cell lines and reagents
Hepatocellular carcinoma cell lines, SK-HeP-1, Huh7 and MHCC97H, were kindly provided by Dr. X. Chen (UCSF, San Francisco); SnU-182 and SnU-387 were kindly provided by the national University of Singapore. Hepg2 was obtained from atCC. all cell lines were cultured in Dulbecco's Modified eagle's Medium (DMeM) supplemented with 10 % FBS, 100 U/ml penicillin and 100 μg/ ml streptomycin (Invitrogen life technologies). XPO1 inhibitors included lMB (Sigma-aldrich), KPt-185 and KPt-330 (Karyopharm therapeutics). For in vitro studies, inhibitors were dissolved in DMSO. For the in vivo study, KPt-330 was dissolved in vehicle solution [(0.6 % (w/v) Pluronic F-68 and 0.6 % (w/v) PVP-K29/32 in sterile water].
Cell proliferation, cell cycle analysis apoptosis assays and measurement of mitochondrial membrane potential 
Western blot analysis
Cell lysates were prepared using lysis buffer [50 mmol/l tris-HCl (pH 7.4), 150 mmol/l naCl, 0.5 % nP-40] containing protease and phosphatase inhibitor cocktails (roche Molecular Biochemicals). Protein samples (50 μg) were subsequently separated on 4-15 % gradient SDSpolyacrylamide gels (Bio-rad) and transferred to polyvinylidene difluoride membranes (Immobilion, Millipore). SuperSignal West Pico and West Dura Chemiluminescent substrates (Pierce Biotechnology, rockford, Il, USa) were used for protein detection. the following primary antibodies were used: anti-XPO1 (BD Biosciences); anti-p53 (DO-1), anti-BCl2, anti-BaX, anti-PUMa, anti-p27, antic-Myc, anti-c-Met (Santa Cruz Biotechnology, Santa Cruz, Ca); and anti-β-actin (Sigma-aldrich).
HCC xenograft murine model all animal experiments were conducted in accordance with the guidelines of Cedars-Sinai research Institute and the national Institute of Health. the protocol was approved by the animal Care and Use Committee at Cedars-Sinai Medical Center Institution (protocol number IaCUC004273), and all efforts were made to minimize animal suffering. Six-week-old female nu/nu athymic nude mice were injected subcutaneously with SK-HeP-1 (5 × 10 6 ) cells suspended in 0.15 ml Matrigel (Basement Membrane Matrix, High Concentration; BD Biosciences). Five mice were randomly assigned to each experimental group: (1) vehicle control (Pluronic F-68/PVP-K29/32); (2) low-dose KPt-330 (10 mg/kg); and (3) high-dose KPt-330 (20 mg/kg). treatments were initiated 1 day after cell implantation and were given by oral gavage 3 times a week on non-consecutive days for 4 weeks. tumor volume was measured by calipers thrice weekly and calculated using the formula: (length × width × depth)/2. all mice were observed for changes in body weight and possible side effects. animals were euthanized on day 33. the tumors were dissected, and either fixed in 10 % formalin, or snap frozen in liquid nitrogen followed by homogenizing on ice for Western blotting.
Statistical analysis
Statistical significance was determined by Student's t test (two tailed), and P values <0.05 were considered statistically significant.
Results
XPO1 inhibition suppresses proliferation of HCC cells in vitro
analysis of XPO1 expression levels in gene expression microarray studies performed on large cohorts of HCC patient samples (accession numbers gSe6764, gSe14520, gSe3500 and gSe14323, available at http:/ /www.ncbi.nlm.nih.gov/geo/), as well as in the Cancer genome atlas (tCga) revealed that XPO1 is overexpressed in HCC compared to normal liver tissue (table 1, Supplementary Fig. 1 ). In addition, Western blot analysis revealed prominent XPO1 expression in HCC cell lines ( Supplementary Fig. 2 ). We, therefore, reasoned that inhibition of XPO1 may have anti-tumor activity in HCC. the effect of the SIne XPO1 inhibitors KPt-276 and (table 2) . Overall, growth inhibition induced by the SIne compounds, as well as lMB, was more prominent in p53 wild-type cells (Hepg2 and SK-HeP-1) than in p53 mutant cells (Huh7, SnU-387, SnU-182 and MHCC97H; Huh7 cells harbor a p53 mutation, yet these cells maintain p53 transcription activity [25] , which may in part explain their high sensitivity to KPt-276 and KPt-330).
KPt-330 induces cell cycle arrest and apoptosis in HCC cell lines to determine whether the observed decrease in cell proliferation is due to cell cycle arrest and/or apoptosis, we measured the effect of KPt-330 on cell cycle progression and apoptotic response in two HCC lines, SK-HeP-1 (p53 wild type) and SnU-387 (p53 mutant). Cells were treated with either increasing concentrations of KPt-330 (SKHeP-1, 20-2,000 nM; SnU-387, 10-1,000 nM) or diluent control for 24 h and cell cycle distributions were determined by PI staining and flow cytometry (Fig. 2a) . Upon incubation with KPt-330, SK-HeP-1 cells showed a dosedependent accumulation in both g1 and g2/M, indicating cell cycle arrest in both of these phases. On the other hand, SnU-387 cells only showed increased fraction of cells in g2/M, and not in g1. to measure the apoptotic response, cells were co-stained with annexin V and PI to monitor early apoptosis, as well as late apoptosis and/or necrosis. after 72 h exposure to KPt-330, both SK-HeP-1 (200 nM) and SnU-387 (300 nM) showed an increase in early, as well as late apoptosis (Fig. 2b) . Western blot analysis showed that following KPt-330 treatment, levels of PUMa (a pro-apoptotic member of the BCl2 family member) were slightly upregulated in SK-HeP-1 cells and were dramatically up-regulated in two other HCC cell lines, Hepg2 and MHCC97H (Fig. 2c) . the levels of the anti-apoptotic protein BCl2 remained unchanged upon KPt-330 treatment, while levels of the pro-apoptotic BCl2 member, BaX, were up-regulated only in MHCC97H cells.
to analyze further the effect of KPt-330 on the apoptotic response in HCC cells, we measured loss of mitochondrial membrane potential, a hallmark of apoptosis. JC-1 is a cationic dye that accumulates in mitochondria. Under normal conditions, JC-1 exists as dimers and accumulates as aggregates in the mitochondria that fluoresce in the red range. In apoptotic and necrotic cells, JC-1 exists in the cytosol as monomers that fluoresce in the green range. SK-HeP-1 and Huh7 cells were treated with increasing consternations of KPt-330 for 48 h and changes in mitochondrial membrane potential were analyzed by FaCS after JC-1 staining. results showed a dose-dependent increase in green fluorescence, indicating loss of mitochondrial membrane potential following KPt-330 treatment (Fig. 2d) .
KPt-330 treatment modulates levels of tumor suppressor and oncogenes to begin evaluating the cellular pathways altered by SIne in HCC cells, we next analyzed the effect of KPt-330 on the protein expression levels of two well-known tumor suppressor XPO1 cargo proteins, p53 and p27 as well as c-Myc and c-Met, two oncogenes with important roles in HCC [3] , and XPO1 itself. SK-HeP-1, Hepg2 and MHCC97H cells were treated with increasing concentrations of KPt-330, and protein expression was analyzed by Western blot (Fig. 3) . to test if XPO1 inhibition affects HCC development in vivo, a xenograft model using SK-HeP-1 HCC cells was established. SK-HeP-1 tumor cells were subcutaneously implanted in athymic nude mice, which were administered either vehicle control or one of two KPt-330 doses (low dose, 10 mg/kg or high dose, 20 mg/kg) by oral gavage 3 days a week. the experiment ended on day 33 due to excessive tumor size in the vehicle-treated control group. Both low and high doses of KPt-330 significantly (P < 0.001 for both doses) inhibited tumor growth (Fig. 4a,  c) . at the beginning of the study, moderate loss in body weight (≤10 %), suggestive of drug toxicity, was observed in the group treated with high-dose KPt-330, but this was partly reversed by the end of the study and did not appear adversely to affect the mice (Fig. 4b) . Concordantly with our in vitro results, Western blot analysis of tumor tissue showed that the protein levels of XPO1 were lower in tumors from KPt-330-treated mice compared with tumors from control mice (Fig. 4d) .
Discussion
the present findings establish the anti-cancer effects of the clinical stage, orally available SIne XPO1 inhibitor, KPt-330, against liver cancer cells, both in vitro and in a xenograft model. Using publicly available data bases, we found that XPO1 is overexpressed in HCC, suggesting that XPO1 may be a therapeutic target in HCC. Our data show that nanomolar concentrations of KPt-330, the first clinically tested SIne compound, leads to growth arrest and apoptosis in six HCC cell lines and suppresses growth of SK-HeP-1 HCC cells in immunocompromised mice with very little toxicity. XPO1 facilitates the nuclear export of over 200 proteins [26, 27] . among XPO1 cargo proteins are key mediators of proliferative signaling pathways, hence, XPO1 is critical for the survival of cancer cells [7, 8] . Yet, the pathways responsible for anti-proliferative effects induced by SIne are not well characterized. a previous study found that p53 status was a major factor determining the apoptotic response to KPt-185 in aMl cell lines and primary cells [15] . However, inhibition of proliferation by SIne in aMl is p53 independent [15, 23] . likewise, SIne exhibits p53-independent anti-cancer activity in nHl [17] , MM [14] and pancreatic cancer cells [24] , potentially through enhancement of p73 and p27 pathways. In our study, KPt-330 reduced proliferation in both p53 wild-type and p53 mutant HCC cells, although the affect was more prominent in p53 wild-type cells. KPt-330 antiproliferative effects in HCC cells were associated with cell cycle arrest and induction of apoptosis. the apoptotic response in HCC cells was accompanied by a dramatic decrease in mitochondrial membrane potential. SIne compounds have been shown to be highly effective in inducing apoptosis in several types of transformed cells, while counterpart normal cells were shown to be much more resistant. Our finding that KPt-330 decreases mitochondrial membrane potential is consistent with a number of earlier studies pointing to the involvement of the intrinsic (mitochondrial) signaling pathway in SIne-induced apoptosis. For example, KPt-185 induced [14, 15] . In other reports, overexpression of the anti-apoptotic protein BCl2 in SInesensitive aMl and t-all cell lines suppressed KPt-185 and KPt-330-induced apoptosis [28] . and finally, a combination of a BCl2 inhibitor with KPt-185 had significant synergistic cytotoxicity in non-small cell lung cancer cells that were otherwise resistance to SIne [29] . p53 is directly involved in the intrinsic apoptosis pathway by interacting with BCl2 family members to induce mitochondrial outer membrane permeabilization [30] . We found that KPt-330 treatment resulted in loss of mitochondrial membrane potential in both p53 wild-type and p53 mutant cells, suggesting that p53 mitochondrial activity may not be essential for KPt-330-induced apoptosis in HCC cells. among several BCl2 family members we tested, induction of PUMa by KPt-330 appeared to be the most prominent in the HCC cells. Interestingly, recent studies suggested that sorafenib induces apoptosis in HCC through an intrinsic mechanism where upregulation of PUMa in a p53-independent manner plays an essential role [31, 32] . taken together with our data, these results suggest that PUMa may play an important common role in mediating apoptotic death of HCC cells in response to targeted therapies.
SIne causes nuclear retention and upregulation of various tumor suppressors including FOXO, p21, p27, IκB and p73 [13, 14, 17] ; on the other hand, SIne compounds induce a reduction in the levels of molecules associated with cancer cell proliferation such as c-Myc [14, 16] . We found that treatment of HCC cell lines with KPt-330 increased levels of p53 and p27 and reduced levels of XPO1, c-Myc and c-Met. Our observation that XPO1 levels decreased after KPt-330 treatment is in agreement with a pervious study showing that KPt-185 reduced XPO1 protein levels in aMl [33] . How inhibition of XPO1 leads to its downregulation is currently unknown. a study using a different XPO1 inhibitor (CBS9106) also noted decreased levels of XPO1 following XPO1 inhibition and suggested that depletion of XPO1 by CBS9106, required the ubiquitin/proteasome pathway [34] .
the transcription factor c-Myc and the tyrosine kinase receptor c-Met are frequently overexpressed and play tumor-promoting roles in HCC [2, 3] . c-Myc and c-Met are not XPO1 target proteins, and it is not clear how XPO1 inhibition leads to reduction in their expression levels. Of note, reduced c-Myc levels following SIne treatment was also reported in MM [14, 16] . also, similar to our observation that KPt-330 down-regulated the c-Met tyrosine kinase receptor in HCC cells, KPt-185 down-regulated the oncogenic tyrosine kinase receptors Flt3 and c-KIt in aMl [33] . Collectively, these data support a model in which SIne inhibition of XPO1 suppresses cancer cells both by leading to nuclear retention/activation of tumor suppressors and by inducing downregulation of oncogenic proteins. given that malignant cells are invariably dependent on abnormal activation of oncogenes and/or inactivation of tumor suppressor genes, this duel effect may provide the basis for the ability of SIne to kill cancer cells while sparing normal cells.
In an era of personalized cancer therapies, in which targeted drugs are often developed against specific driver mutations or tumor suppressors, XPO1 inhibition by SIne appears to be fairly broad without requiring a particular tumor type or cancer cell genotype to be effective. Consequently, SIne show robust anti-cancer activity in preclinical models for a growing list of hematologic malignancies and solid tumors. Our results suggest that SIne XPO1 antagonists are promising clinical candidates for HCC, a disease for which current treatment options are severely limited.
